ANA S. CVETANOVIC1,2,*, MATTEO LAMBERTINI3,4, KEVIN PUNIE5, GORANA G. MATOVINA BRKO6, NIKOLA D. ZIVKOVIC7,8, MAJA J. POPOVIC6,9, MARIJANA M. MILOVIC KOVACEVIC10, LAZAR S. POPOVIC6,9
Oncology Research, Vol.32, No.8, pp. 1309-1322, 2024, DOI:10.32604/or.2024.049743
- 17 July 2024
Abstract Oncofertility is an extremely significant topic that is increasingly being discussed owing to increased evidence indicating that fertility preservation does not affect the treatment outcomes of patients with cancer but significantly contributes to preserving life quality. The effect of chemotherapy can range from minimal effects to complete ovarian atrophy. Limited data are available on the effects of monoclonal antibodies and targeted therapies on the ovaries and fertility. Temporary ovarian suppression by administering a gonadotropin-releasing hormone agonist (GnRHa) during chemotherapy decreases the gonadotoxic effect of chemotherapy, thereby diminishing the chance of developing premature ovarian insufficiency (POI).… More >
Graphic Abstract
Login
Register
